If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
DNA-binding proteins are proteins that have DNA-binding domains and thus have a specific or general affinity for single- or double-stranded DNA. Sequence-specific DNA-binding proteins generally interact with the major groove of B-DNA, because it exposes more functional groups that identify a base pair.
== See also == Androgenic hair Bearded lady Ferriman-Gallwey score Hair removal Hypertrichosis Laser hair removal Petrus Gonsalvus Polyendocrine metabolic ovarian syndrome (PMOS) Pubic hair Social model of disability Trichophilia
Cammack R, Jackson RH, Cornish-Bowden A, Cole JA (1982). "Electron-spin-resonance studies of the NADH-dependent nitrite reductase from Escherichia coli K12". Biochem. J. 207 (2): 333–9. doi:10.1042/bj2070333. PMC 1153865. PMID 6297458. Lazzarini RA; Atkinson DE (1961). "A triphosphopyridine nucleotide-specific nitrite reductase from Escherichia coli". J. Biol. Chem. 236 (12): 3330–3335. doi:10.1016/S0021-9258(18)94019-6. PMID 14463130. Nicholas DJ, Medina A, Jones OT (1960). "A nitrite reductase from Neurospora crassa". Biochim. Biophys. Acta. 37 (3): 468–76. doi:10.1016/0006-3002(60)90503-5. PMID 14426899. Taniguchi H, Mitsui H, Nakamura K, Egami F. "Ann. Acad. Sci. Fenn. Ser. A II 60 (1955) 200". {{cite journal}}: Cite journal requires |journal= (help) Colandene JD, Garrett RH (1996). "Functional dissection and site-directed mutagenesis of the structural gene for NAD(P)H-nitrite reductase in Neurospora crassa". J. Biol. Chem. 271 (39): 24096–104. doi:10.1074/jbc.271.39.24096. PMID 8798648.
Sources: en.wikipedia.org
Furthermore, Oxgr1 gene knockout mice drinking sodium bicarbonate-rich water developed metabolic alkalosis (body tissue pH levels higher than normal) that was associated with blood bicarbonate levels significantly higher and blood chloride levels significantly lower than those in control mice drinking the sodium bicarbonate-rich water. Several other studies confirmed these findings and reported that cells in the proximal tubules of mice synthesize α-ketoglutarate and either broke it down thereby reducing its urine levels or secreted it into the tubules' lumens thereby increasing its urine levels. Another study showed that a) In silico computer simulations strongly suggested that α-ketoglutarate bound to mouse OXGPR1; b) suspensions of canal duct cells isolated from the collecting ducts, loops of Henle, vasa recta, and interstitium of mouse kidneys raised their cytosolic ionic calcium, i.e., Ca2+ levels in response to α-ketoglutarate but this response (which is an indicator of cell activation) was blocked by pretreating the cells with montelukast; and c) compared to mice not treated with streptozotocin, streptozotocin-induced diabetic mice (an animal disease model of diabetes) urinated only a small amount of the ionic sodium (Na+) that they drank or received by intravenous injections; montelukast reversed this defect in the streptozotocin-pretreated mice.
1993/3173) Education (Individual Pupils' Achievements) (Information) Regulations 1993 (S.I. 1993/3182) Education (European Economic Area) (Amendment) Regulations 1993 (S.I. 1993/3183) Education (European Economic Area) (Scotland) Regulations 1993 (S.I. 1993/3184) Liquor Licensing (Fees) (Scotland) Order 1993 (S.I. 1993/3185) Advice and Assistance (Assistance by Way of Representation) (Scotland) Amendment (No. 2) Regulations 1993 (S.I. 1993/3186) Advice and Assistance (Financial Limit) (Scotland) Regulations 1993 (S.I. 1993/3187) Education (Grant–maintained Schools) (Initial Sponsor Governors) Regulations 1993 (S.I. 1993/3188) Education (Acquisition of Grant-maintained Status) (Ballot Information) Regulations 1993 (S.I. 1993/3189) Supreme Court Fees (Amendment) Order 1993 (S.I. 1993/3191) Cod and Saithe (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3192) Haddock, Hake, Nephrops, Plaice and Sole (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3193) Social Security (Severe Disablement Allowance) Amendment Regulations 1993 (S.I. 1993/3194) Doncaster Borough Council (North Bridge Relief Road) (Crossing of Navigable Waterway (Sheffield and South Yorkshire Navigation River Don New Cut)) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/3195) Education (Distribution by Schools of Information about Further Education Institutions) (England) Regulations 1993 (S.I. 1993/3197) Nitrate Sensitive Areas (Designation) (Amendment) Order 1993 (S.I. 1993/3198) Broadcasting (Restrictions on the Holding of Licences) (Amendment) Order 1993 (S.I.
However, introducing salinity into the fluid raises the critical point to higher temperatures and pressures. The critical point of seawater (3.2 wt. % NaCl) is 407 °C (765 °F) and 298.5 bars, corresponding to a depth of ~2,960 m (9,710 ft) below sea level. Accordingly, if a hydrothermal fluid with a salinity of 3.2 wt. % NaCl vents above 407 °C (765 °F) and 298.5 bars, it is supercritical. Furthermore, the salinity of vent fluids have been shown to vary widely due to phase separation in the crust. The critical point for lower salinity fluids is at lower temperature and pressure conditions than that for seawater, but higher than that for pure water. For example, a vent fluid with a 2.24 wt. % NaCl salinity has the critical point at 400 °C (752 °F) and 280.5 bars. Thus, water emerging from the hottest parts of some hydrothermal vents can be a supercritical fluid, possessing physical properties between those of a gas and those of a liquid.Examples of supercritical venting are found at several sites. Sister Peak (Comfortless Cove Hydrothermal Field, 4°48′S 12°22′W, depth 2,996 m or 9,829 ft) vents low salinity phase-separated, vapor-type fluids. Sustained venting was not found to be supercritical but a brief injection of 464 °C (867 °F) was well above supercritical conditions. A nearby site, Turtle Pits, was found to vent low salinity fluid at 407 °C (765 °F), which is above the critical point of the fluid at that salinity.
Sources: en.wikipedia.org
== External links == "Melanocortin Receptors: MC2". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-07-23. MC2+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human MC2R genome location and MC2R gene details page in the UCSC Genome Browser.
===== Fifth generation ===== Since the mid-1990s, the fifth generation of silicone-gel breast implant is made of a high-strength, highly cohesive silicone gel that mostly eliminates the occurrences of filler leakage ("silicone gel bleed") and of the migration of the silicone filler from the implant pocket to elsewhere in the woman's body. These implants are commonly referred to as "gummy bear breast implants" for their firm, pliant consistency, which is similar to gummy candies. The studies Experience with Anatomical Soft Cohesive Silicone gel Prosthesis in Cosmetic and Reconstructive Breast Implant Surgery (2004) and Cohesive Silicone gel Breast Implants in Aesthetic and Reconstructive Breast Surgery (2005) reported low incidence-rates of capsular contracture and of device-shell rupture; and greater rates of improved medical-safety and technical-efficacy than that of early generation breast implant devices.
l-Histidine is an essential amino acid that is not synthesized de novo in humans. Humans and other animals must ingest histidine or histidine-containing proteins. The biosynthesis of histidine has been widely studied in prokaryotes such as E. coli. Histidine synthesis in E. coli involves eight gene products (His1, 2, 3, 4, 5, 6, 7, and 8) and it occurs in ten steps. This is possible because a single gene product has the ability to catalyze more than one reaction. For example, as shown in the pathway, His4 catalyzes four different steps in the pathway. Histidine is synthesized from phosphoribosyl pyrophosphate (PRPP), which is made from ribose-5-phosphate by ribose-phosphate diphosphokinase in the pentose phosphate pathway. The first reaction of histidine biosynthesis is the condensation of PRPP and adenosine triphosphate (ATP) by the enzyme ATP-phosphoribosyl transferase. ATP-phosphoribosyl transferase is indicated by His1 in the image. His4 gene product then hydrolyzes the product of the condensation, phosphoribosyl-ATP, producing phosphoribosyl-AMP (PRAMP), which is an irreversible step. His4 then catalyzes the formation of phosphoribosylformiminoAICAR-phosphate, which is then converted to phosphoribulosylformimino-AICAR-P by the His6 gene product. His7 splits phosphoribulosylformimino-AICAR-P to form d-erythro-imidazole-glycerol-phosphate. After, His3 forms imidazole acetol-phosphate releasing water. His5 then makes l-histidinol-phosphate, which is then hydrolyzed by His2 making histidinol.
Despite the limited clinical experience in these decades, that era is remarkable for the demonstration of the role technology has in neuromodulation, and there are some case reports of deep brain stimulation for a variety of problems, real or perceived. Delgado hinted at the power of neuromodulation with his implants in the bovine septal region and the ability of electrical stimulation to blunt or alter behavior. Further attempts at this "behavioral modification" in humans were difficult and seldom reliable, and contributed to the overall lack of progress in central nervous system neuromodulation from that era. Attempts at intractable pain syndromes were met with more success, but again hampered by the quality of technology. In particular, the so-called DBS "zero" electrode (consisting of a contact loop on its end) had an unacceptable failure rate, and revisions were fraught with more risk than benefit. Overall, attempts at using electrical stimulation for "behavioral modification" were difficult and seldom reliable, slowing development of DBS. Attempts at addressing intractable pain syndromes with DBS were met with more success, but again hampered by the quality of technology. A number of physicians who hoped to address hitherto intractable problems sought development of more specialized equipment; for instance, in the 1960s, Wall's colleague Bill Sweet recruited engineer Roger Avery to make an implantable peripheral nerve stimulator. Avery started the Avery Company, which made a number of implantable stimulators.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.